SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern

The company's first marketed drug, Zulresso (brexanolone), was approved by the FDA in 2019 as the first-ever FDA-approved treatment for adults with postpartum depression (PPD). SAGE markets Zurzuvae in partnership with drug giant Biogen (BIIB) . Sage and BIIB are focused on establishing Zurzuvae as a first-line therapy and the standard of care for women with PPD. Image Source: Zacks Investment Research Last month, the company reported that the phase II SURVEYOR study evaluating dalzanemdor as a potential tr ...